



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: [us.340B@gsk.com](mailto:us.340B@gsk.com)

September 12, 2025

**Notice to 340B Covered Entities Located in Oregon - Update to GSK's 340B Contract Pharmacy Policy  
Effective September 28, 2025**

Dear Valued 340B Customer:

I am writing to inform you that GlaxoSmithKline (GSK) is updating its 340B Contract Pharmacy Policy that will alter its approach to distributing and accessing products purchased at the 340B price.

To ensure compliance with Oregon state law requirements (HB 2385), GSK is implementing changes to its Contract Pharmacy Policy (effective since May 1, 2023).

Effective September 28, 2025, GSK will make the following modifications to its Policy for 340B covered entities located in Oregon:

- Oregon-based covered entities will be able to place "Bill to/Ship to" replenishment orders through all their HRSA designated contract pharmacies located within Oregon, for products not part of a GSK limited pharmacy network.
- For GSK specialty/oncology products part of a limited pharmacy network, Oregon covered entities can designate unlimited contract pharmacies that are part of GSK's limited pharmacy network. Specialty/oncology designated contract pharmacies must be listed on the HRSA OPA database as a covered entity contract pharmacy. (See network below).
- GSK will allow covered entities' "Bill to/Ship to" replenishment orders on or after September 28, 2025, associated with the above policy exceptions.

GSK continues to monitor state level 340B contract pharmacy requirements and may make additional modifications to the above requirements, including re-instituting its May 1, 2023 Policy.

If you have questions regarding the changes to GSK's 340B Contract Pharmacy Policy, please contact GSK at [support@340Besp.com](mailto:support@340Besp.com).



2929 Walnut Street, Suite 1700  
Philadelphia, PA 19104  
Email: us.340B@gsk.com

## GSK Limited Pharmacy Networks (as of 30 June 2025)

| GSK Limited Pharmacy Network             | Benlysta | Nucala | Zejula | Flolan | Ojjaara |
|--|----------|--------|--------|--------|---------|
| AcariaHealth, Inc.                       | X        | X      |        |        |         |
| Accredo Health Group, Inc.               | X        | X      | X      | X      |         |
| Walgreens Specialty Pharmacy             | X        | X      |        |        |         |
| Amber Specialty Pharmacy                 | X        |        |        |        |         |
| Meijer Specialty Pharmacy                | X        |        |        |        |         |
| Biologics, Inc.                          |          |        | X      |        | X       |
| Caremark, LLC                            | X        | X      | X      | X      |         |
| CenterWell Pharmacy                      | X        | X      |        |        |         |
| BioPlus Specialty Pharmacy Services, LLC | X        | X      |        |        |         |
| Prime Therapeutics                       | X        |        |        |        |         |
| Optum Rx                                 | X        | X      | X      |        |         |
| Reliance Rx                              | X        |        |        |        |         |
| Senderra Rx                              | X        |        |        |        |         |
| Onco360                                  |          |        |        |        | X       |

X indicates the GSK product eligible to be dispensed from the given pharmacy